UNSPSC 51292601: Clorazepate

This classification denotes an anti-anxiety agent, anticonvulsant, and gaba modulator with the molecular formula C16H11ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D51WO0G0L4, chemically known as 7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1h-1,4-benzodiazepine-3-carboxylic acid but generally known as clorazepate, which bears US NIH Compound Identifier 2809. Most nations schedule clorazepate under HS 29339100 and SITC 51577. SMILES: C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)CL)C(=O)O.

UNSPSC 51292601 Clorazepate, a Commodity code, covers individual pharmaceutical products that state and local governments procure for health and human services delivery. Recent solicitations show state and local buyers purchasing specific medications and pharmaceutical products through competitive bidding and cooperative purchasing frameworks, though the three opportunities in the recent record span naloxone procurement, pharmacy benefit program inquiry, and generic multi-source pharmaceutical contracting rather than clorazepate specifically. State and local issuing bodies soliciting under pharmaceutical codes include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple state and local jurisdictions. Seminole County, Florida, represents municipal-level health procurement; Texas Health and Human Services Commission represents state-level pharmacy benefit administration; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represents multi-jurisdictional cooperative contracting serving state agencies and local government facilities across participating states including Oregon. The scope of work involves supply agreements with fixed or negotiated pricing, compliance with federal drug supply chain security and good manufacturing practice standards, delivery to specified government locations, and adherence to insurance and employment verification requirements.

Activity in this code spans Florida, Texas, and the upper Midwest region participating in MMCAP. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities as a preliminary step before formal competitive procurement. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, with a proposal deadline of March 26, 2026 and contract effectiveness July 1, 2026; vendors must maintain relationships with at least two of three specified wholesalers and comply with cGMP and Drug Supply Chain Security Act certification, with pricing weighted at 75 percent of evaluation criteria and administrative fees set at 3 percent of contract purchases.